Skip to main content

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026 The transaction marks Angelini Pharma’s entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases Closing is expected in the third quarter of 2026ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) — Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage...

Continue reading

Financial Calendar 2026 – update

ANNOUNCEMENTA.P. Møller – Mærsk A/S – Financial Calendar 2026 – updateThe interim report for the 2nd quarter will be published on 13 August 2026 and not on 6 August 2026 as previously stated in the Company’s financial calendar. The Company’s financial calendar for the remainder of 2026 is as follows:A.P. Møller – Mærsk A/S plans to publish itsInterim Report for the 2nd quarter on 13 August 2026 Interim Report for the 3rd quarter on 5 November 2026Copenhagen, 7 May 2026 Contact person: Head of Investor Relations, Martin Dunwoodie, tel. +45 3363 3484                                                                                                                                                                           Page 1 of 1AttachmentFinancial Calendar 2026 – update

Continue reading

Shell plc First Quarter 2026 Interim Dividend

London, May 7, 2026 − The Board of Shell plc (the “Company”) (XLON: SHEL, XNYS: SHEL, XAMS: SHELL) today announced an interim dividend in respect of the first quarter of 2026 of US$ 0.3906 per ordinary share. Details relating to the first quarter 2026 interim dividendPer ordinary share(GB00BP6MXD84)   Q1 2026Shell Shares (US$) 0.3906Shareholders will be able to elect to receive their dividends in US dollars, euros or pounds sterling. An alternative ‘Electronic Election Entitlement’ (‘EEE’) process is available in CREST for dividends with options elections. Absent any valid election to the contrary, persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros. Absent any valid election to the contrary, shareholders (both holding in certificated and uncertificated form (CREST members))...

Continue reading

Solar A/S: Nr. 11 2026 Q1 results at the lower end of our expected range

March showed growth across most markets, while Q1 performance came in at the lower end of expectations, impacted by severe winter in February.. CEO Jens Andersen says:“Q1 revenue and EBITDA were at the lower end of our expected range, primarily due to the severe winter, particularly in February, which impacted activity levels, most notably in our infrastructure business. The impact eased in March, when revenue growth was delivered across most markets. Several suppliers have announced significant price increases, primarily affecting oil-based products. For Solar, this may lead to higher cyclical inventory gains in the short term, while also potentially having a negative impact on demand. The integration of Sonepar Norge is ahead of schedule, with integration costs DKK 10m lower than initially expected, and our logistics centre in...

Continue reading

Oma Savings Bank Plc’s Interim Report 1.1.-31.3.2026: The volume of new loans began to increase – capital adequacy continued to strengthen – the comparable profit before tax for the first quarter improved to EUR 13.7 million

Released: 07.05.2026 Category: Interim Report OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 7 MAY 2026 AT 8.45 A.M. EEST, INTERIM REPORT Q1 Oma Savings Bank Plc’s Interim Report 1.1.-31.3.2026: The volume of new loans began to increase – capital adequacy continued to strengthen – the comparable profit before tax for the first quarter improved to EUR 13.7 million This release is a summary of Oma Savings Bank’s (OmaSp) January-March 2026 Interim Report, which can be read from the pdf file attached to this stock exchange release and on the Company’s web pages www.omasp.fi CEO Karri Alameri: The year 2026 opened in an operating environment characterised by geopolitical tension, moderate economic growth and uncertainty in the financial markets. Relatively low market interest rates are continuing to put pressure on banks’ net interest income,...

Continue reading

DEMIRE remains operationally stable in the first quarter of 2026 – guidance confirmed

DEMIRE remains operationally stable in the first quarter of 2026 – guidance confirmed • Rental income after disposals at EUR 11.6 million (Q1 2025: EUR 14.0 million)• FFO I at EUR 0.3 million (Q1 2025: EUR 2.1 million) – decline primarily due to property sales• 2026 forecast confirmed: rental income EUR 41.5 to 43.5 million; FFO I EUR -1.0 to 1.0 million Langen, 7 May 2026. In the first quarter of 2026, DEMIRE Deutsche Mittelstand Real Estate AG (ISIN: DE000A0XFSF0) performed in line with operational plans based on its reduced portfolio. The results were in line with previously communicated expectations and underscore the high degree of predictability of the business model. Rental income and FFO I in line with expectations following disposals – EBIT significantly improved due to lower fair value adjustments on properties As expected, rental...

Continue reading

The Feronord consortium has won the OL32 Skavsta contract, part of the East Link rail project south of Stockholm, Sweden

Press release7 May 2026 The Feronord consortium has won the OL32 Skavsta contract, part of the East Link rail project south of Stockholm, Sweden. The Feronord consortium, comprising Infrakraft, Bouygues Travaux Publics, and Colas Rail (Colas), has been selected by Trafikverket, the Swedish transport administration, to carry out contract OL32 for the East Link project. This contract covers the construction of approximately 36 kilometres of railway line, including major earthworks and the construction of 28 bridges and 3 viaducts, one of which is a major structure spanning 1.4 kilometres. A strategic project and a new model of partnership The East Link project is a key infrastructure element of Sweden’s national transport development programme. It is designed to increase rail network capacity, improve travel between the Stockholm/Mälardalen...

Continue reading

Interim Reports Q1 2026 – Nykredit Realkredit Group

To Nasdaq Copenhagen A/S7 May 2026Nykredit today announces its Q1 Interim Reports 2026 of: Nykredit A/S, CVR no 12 71 92 48Nykredit Realkredit A/S, CVR no 12 71 92 80                 Michael Rasmussen, Group Chief Executive, comments on the Nykredit Group’s Q1 Interim Financial Statements:We are pleased to present a satisfactory interim profit after tax of DKK 2.7 billion for the Nykredit Group. Generally, we expect continued progress in the Group’s core business for the rest of the year and maintain our guidance for a full-year profit after tax of DKK 10.25-11.25 billion.In the first quarter of the year, we achieved business and customer growth, increased lending and growing market shares across the Group’s core business. This was all achieved alongside the efficient merger of Nykredit and Spar Nord, where,...

Continue reading

Iveco Group 2026 First Quarter Results

The following is an extract from the “Iveco Group 2026 First Quarter Results” press release(*). The complete press release can be accessed by visiting the media section of the Iveco Group corporate website: https://www.ivecogroup.com/media/corporate_press_releases or consulting the accompanying PDF: A quarter focused on quality improvements against a backdrop of industrial volatility.Defence sale completed in the quarter. Tata Motors Tender Offer expected to close by Q3 2026. Consolidated revenues amounted to €2,828 million compared to €2,806 million in Q1 2025. Net revenues of Industrial Activities were €2,766 million compared to €2,736 million in Q1 2025, mainly due to higher volumes in Bus, partially offset by negative volume in Truck in South America and an adverse foreign exchange rate impact. Adjusted EBIT loss was €55 million compared...

Continue reading

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9 in New Orleans, LA. Across multiple presentations, the Company and its collaborators will share interim outcomes of a long-term extension study for leniolisib in pediatric patients aged 4 to 11 years with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS). The presentations will also include clinical data from expanded access use of leniolisib to treat immune dysregulation in patients with Common Variable Immunodeficiency (CVID) and CVID-like disorders, as well as further insight into APDS and additional primary immunodeficiencies (PIDs) with immune dysregulation. Two phase II...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.